HintzenR. Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents – Commentary. Mult Scler J2016; 22(13): 1653–1654.
GhezziABanwellBBoykoA. The management of multiple sclerosis in children: A European view. Mult Scler2010; 16(10): 1258–1267.
4.
Amit Bar-OrAHintzenRDaleR. Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology2016; 87(Suppl. 2): S12–S19.
5.
VerheyLHSignoriAArnoldDL. Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology2013; 81(14): 1215–1221.